194 Followers on Owler

EmendoBio

Read more
David Baram's photo - President & CEO of EmendoBio

President & CEO

David Baram

CEO Approval Rating

87/100

Est. Annual Revenue
$2.9M
Agree?
Est. Employees
50
Agree?
Funding
$61M

EmendoBio Competitors and Alternatives

1
3
2
See more competitor data

EmendoBio News

EmendoBio Press Releases

EmendoBio Headquarters

400 W 61st Street

New York, New York10069

917-675-5585

Driving Directions »

EmendoBio Summary

ABOUT

Overview

Emendo is a biotechnology company that develops and commercializes gene-editing therapeutics for the treatment of genetic diseases. EmendoBio was founded in 2015. EmendoBio's headquarters is located in New York, New York, USA 10069. EmendoBio's Presi...

CEO

EmendoBio's President & CEO, David Baram, currently has an approval rating of 87%. EmendoBio's primary competitors are Spotlight Therapeutics, Beam & Editas Medicine.

Acquisitions

There have been no acquisitions found related to EmendoBio

Investments

Recent investment data cannot be found related to EmendoBio

Frequently Asked Questions about EmendoBio

  1. When was EmendoBio founded?

    EmendoBio was founded in 2015
  2. Who is EmendoBio's CEO?

    EmendoBio's CEO is David Baram
  3. How much revenue does EmendoBio generate?

    EmendoBio generates $2.9M in revenue
  4. How much funding does EmendoBio have?

    EmendoBio has historically raised $61M in funding
  1. Where is EmendoBio's headquarters?

    EmendoBio's headquarters is in New York New York, USA
  2. How many employees does EmendoBio have?

    EmendoBio has 50 employees
  3. What sector does EmendoBio operate in?

    EmendoBio is in Biotechnology
  4. Who are EmendoBio's competitors?

    EmendoBio's top competitors are Spotlight Therapeutics, Beam, Editas Medicine

Trending Companies